Orchestra BioMed Holdings, Inc. Comprehensive Income
Orchestra BioMed Holdings, Inc. (OBIO) reported Comprehensive Income of -$23.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$23.80M.
- Orchestra BioMed Holdings, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$20.79M.
- Orchestra BioMed Holdings, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $6.26M.
- Orchestra BioMed Holdings, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$20.80M.
- Orchestra BioMed Holdings, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$52.69M.
- Orchestra BioMed Holdings, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$60.96M.
- Orchestra BioMed Holdings, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$49.12M.
- Orchestra BioMed Holdings, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$33.62M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$23.80M 10-Q · filed 2026-08-10 | -$44.59M 10-Q · filed 2026-08-10 | -$38.33M derived: sum of 3 quarters · filed 2026-08-10 | -$59.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$20.79M 10-Q · filed 2026-05-12 | -$14.53M derived: sum of 2 quarters · filed 2026-05-12 | -$35.33M derived: sum of 3 quarters · filed 2026-05-12 | -$54.71M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$14.54M derived: sum of 2 quarters · filed 2026-03-12 | -$33.92M derived: sum of 3 quarters · filed 2026-08-10 | -$52.69M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$20.80M 10-Q · filed 2025-11-10 | -$40.18M derived: sum of 2 quarters · filed 2026-08-10 | -$58.95M 10-Q · filed 2025-11-10 | -$75.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$19.38M 10-Q · filed 2026-08-10 | -$38.15M 10-Q · filed 2026-08-10 | -$54.35M derived: sum of 3 quarters · filed 2026-08-10 | -$69.66M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$18.77M 10-Q · filed 2026-05-12 | -$34.97M derived: sum of 2 quarters · filed 2026-05-12 | -$50.28M derived: sum of 3 quarters · filed 2026-05-12 | -$66.27M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$31.51M derived: sum of 2 quarters · filed 2026-03-12 | -$47.50M derived: sum of 3 quarters · filed 2026-03-12 | -$60.96M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$15.30M 10-Q · filed 2025-11-10 | -$31.30M derived: sum of 2 quarters · filed 2025-11-10 | -$44.76M 10-Q · filed 2025-11-10 | -$57.51M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$15.99M 10-Q · filed 2025-08-12 | -$29.46M 10-Q · filed 2025-08-12 | -$42.21M derived: sum of 3 quarters · filed 2025-08-12 | -$55.50M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$13.46M 10-Q · filed 2025-05-12 | -$26.21M derived: sum of 2 quarters · filed 2025-05-12 | -$39.51M derived: sum of 3 quarters · filed 2025-05-12 | -$51.62M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$12.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$26.05M derived: sum of 2 quarters · filed 2025-03-31 | -$38.16M derived: sum of 3 quarters · filed 2025-03-31 | -$49.12M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$13.30M 10-Q · filed 2024-11-12 | -$25.40M derived: sum of 2 quarters · filed 2024-11-12 | -$36.37M 10-Q · filed 2024-11-12 | -$46.13M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$12.11M 10-Q · filed 2024-08-12 | -$23.07M 10-Q · filed 2024-08-12 | -$32.83M derived: sum of 3 quarters · filed 2024-08-12 | -$43.11M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$10.97M 10-Q · filed 2024-05-13 | -$20.73M derived: sum of 2 quarters · filed 2024-05-13 | -$31.01M derived: sum of 3 quarters · filed 2024-05-13 | -$38.85M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$9.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$20.04M derived: sum of 2 quarters · filed 2024-03-27 | -$27.89M derived: sum of 3 quarters · filed 2024-03-27 | -$33.62M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$10.28M 10-Q · filed 2023-11-13 | -$18.13M derived: sum of 2 quarters · filed 2023-11-13 | -$23.86M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$7.85M 10-Q · filed 2023-08-10 | -$13.58M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$5.73M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |